Iparomlimab is a monoclonal IgG4κ antibody that targets the human programmed death-1 receptor (PD-1, also known as CD279 or PDCD1). This antibody is engineered to bind specifically to the PD-1 receptor, a critical molecule involved in the negative regulation of immune responses and a key therapeutic target in oncology. Iparomlimab is composed of a γ4-chain and a κ-chain of the human monoclonal antibody PSB103, linked by a disulfide bond to form a stable dimer. This biologic is primarily utilized in research focused on cancer immunotherapy, investigating the modulation of immune checkpoints that are pivotal in tumor immune evasion.
Iparomlimab is a monoclonal IgG4κ antibody that targets the human programmed death-1 receptor (PD-1, also known as CD279 or PDCD1). This antibody is engineered to bind specifically to the PD-1 receptor, a critical molecule involved in the negative regulation of immune responses and a key therapeutic target in oncology. Iparomlimab is composed of a γ4-chain and a κ-chain of the human monoclonal antibody PSB103, linked by a disulfide bond to form a stable dimer. This biologic is primarily utilized in research focused on cancer immunotherapy, investigating the modulation of immune checkpoints that are pivotal in tumor immune evasion.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
Please check COA/MSDS for correct molecular weight.
Calculate the dilution required to prepare a stock solution.This equation is commonly abbreviated as: C1V1 = C2V2
Frequently Asked Questions
What are Biosimilar Antibodies?
Biosimilar antibodies are research-grade recombinant antibodies designed to closely resemble approved therapeutic antibodies in terms of amino acid sequence, structural characteristics, and biological activity. These antibodies are generated using recombinant expression technologies and retain the same variable regions as their corresponding reference therapeutics, thereby preserving target specificity and binding affinity. Owing to these properties, biosimilar antibodies serve as reliable and cost-effective research reagents for applications in drug discovery, pharmacological studies, and basic biomedical research.
Research-grade biosimilar antibodies have been successfully expressed and functionally validated against a wide range of widely studied targets. These antibodies can be directly utilized as positive control reagents in drug discovery programs, as well as reference tools for rapid verification of the biological functions of target proteins in biochemical and cellular assays.
